Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism

[1]  Kari A. Johnson,et al.  Selective Actions of Novel Allosteric Modulators Reveal Functional Heteromers of Metabotropic Glutamate Receptors in the CNS , 2014, The Journal of Neuroscience.

[2]  R. Hodgson,et al.  A2A receptor antagonists do not induce dyskinesias in drug-naive or l-dopa sensitized rats , 2013, Brain Research Bulletin.

[3]  F. Nicoletti,et al.  Early Life Stress Causes Refractoriness to Haloperidol-Induced Catalepsy , 2013, Molecular Pharmacology.

[4]  F. Gasparini,et al.  Metabotropic Glutamate Receptors for Parkinson's Disease Therapy , 2013, Parkinson's disease.

[5]  C. Bass,et al.  Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and delta opioid systems , 2013, Journal of neurochemistry.

[6]  G. Fisone,et al.  Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease , 2013, Neuropharmacology.

[7]  KouichiC . Nakamura,et al.  Dichotomous Organization of the External Globus Pallidus , 2012, Neuron.

[8]  Kuei Yuan Tseng,et al.  CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation , 2012, Front. Pharmacol..

[9]  F. Nicoletti,et al.  Metabotropic glutamate receptors: From the workbench to the bedside , 2011, Neuropharmacology.

[10]  S. Bicciato,et al.  Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation , 2010, Nature Medicine.

[11]  L. Grégoire,et al.  Effect of l‐Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys , 2010, Journal of neurochemistry.

[12]  P Jeffrey Conn,et al.  Glutamate receptors as therapeutic targets for Parkinson's disease. , 2009, CNS & neurological disorders drug targets.

[13]  A. Bittner,et al.  Dopamine Depletion Induces Distinct Compensatory Gene Expression Changes in DARPP-32 Signal Transduction Cascades of Striatonigral and Striatopallidal Neurons , 2009, The Journal of Neuroscience.

[14]  J. Brotchie,et al.  Mechanisms compensating for dopamine loss in early Parkinson disease , 2009, Neurology.

[15]  R. Moratalla,et al.  Expression and Function of CB1 Receptor in the Rat Striatum: Localization and Effects on D1 and D2 Dopamine Receptor-Mediated Motor Behaviors , 2008, Neuropsychopharmacology.

[16]  R. Sanchez-Pernaute,et al.  Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates , 2008, NeuroImage.

[17]  F. Fonseca,et al.  Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1 , 2008, Neuropharmacology.

[18]  Vesna Sossi,et al.  Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study , 2007, Annals of neurology.

[19]  M. Amalric,et al.  Targeting Group III Metabotropic Glutamate Receptors Produces Complex Behavioral Effects in Rodent Models of Parkinson's Disease , 2007, The Journal of Neuroscience.

[20]  Robert C. Malenka,et al.  Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models , 2007, Nature.

[21]  Mauro Piacentini,et al.  Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders , 2007, Journal of neurochemistry.

[22]  T. Freund,et al.  Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia , 2006, Neuroscience.

[23]  G. Bernardi,et al.  Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia , 2006, Neurobiology of Disease.

[24]  A. Verkhratsky,et al.  Changes in mGlu5 receptor expression in the basal ganglia of reserpinised rats. , 2006, European journal of pharmacology.

[25]  F. Nicoletti,et al.  Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine , 2006, The Journal of Neuroscience.

[26]  P. Jeffrey Conn,et al.  Metabotropic glutamate receptors in the basal ganglia motor circuit , 2005, Nature Reviews Neuroscience.

[27]  E. Bézard,et al.  Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease , 2005, Neuropharmacology.

[28]  J. Marshall,et al.  Glutamic Acid Decarboxylase 67 mRNA Regulation in Two Globus Pallidus Neuron Populations by Dopamine and the Subthalamic Nucleus , 2004, The Journal of Neuroscience.

[29]  Giuseppe Battaglia,et al.  Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice , 2004, The Journal of Neuroscience.

[30]  L F Agnati,et al.  Receptor heteromerization in adenosine A2A receptor signaling , 2003, Neurology.

[31]  O. Valenti,et al.  Modulation of Inhibitory Transmission in the Rat Globus Pallidus by Activation of mGluR4 , 2003, Annals of the New York Academy of Sciences.

[32]  P Jeffrey Conn,et al.  Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse , 2003, The Journal of Neuroscience.

[33]  Erwan Bezard,et al.  Presymptomatic compensation in Parkinson's disease is not dopamine-mediated , 2003, Trends in Neurosciences.

[34]  Michael A King,et al.  Particle detection, number estimation, and feature measurement in gene transfer studies: optical fractionator stereology integrated with digital image processing and analysis. , 2002, Methods.

[35]  S. Duty,et al.  Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract , 2002, Neuropharmacology.

[36]  P. Somogyi,et al.  Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS , 2002, Neuroscience.

[37]  G. Marsicano,et al.  Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain , 2002, Neuroscience.

[38]  V. Sossi,et al.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.

[39]  T. Hökfelt,et al.  Dopamine D1 receptor modulation of glutamate receptor messenger RNA levels in the neocortex and neostriatum of unilaterally 6-hydroxydopamine-lesioned rats , 1999, Neuroscience.

[40]  K. Kovács,et al.  Invited review c-Fos as a transcription factor: a stressful (re)view from a functional map , 1998, Neurochemistry International.

[41]  K. Starke,et al.  Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum , 1998, Neuroscience.

[42]  P. Calabresi,et al.  Abnormal Synaptic Plasticity in the Striatum of Mice Lacking Dopamine D2 Receptors , 1997, The Journal of Neuroscience.

[43]  J. Surmeier,et al.  D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. , 1997, Journal of neurophysiology.

[44]  E. Abercrombie,et al.  Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D2 receptors. , 1996, European journal of pharmacology.

[45]  J. Roder,et al.  Impaired Cerebellar Synaptic Plasticity and Motor Performance in Mice Lacking the mGluR4 Subtype of Metabotropic Glutamate Receptor , 1996, The Journal of Neuroscience.

[46]  E. Hirsch,et al.  Effects of l-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum , 1995, Neuroscience.

[47]  C. Marsden,et al.  Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease , 1995, Neuroscience.

[48]  A. Parent,et al.  Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys , 1994, Neuroreport.

[49]  D. Mash,et al.  Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons , 1994, Annals of neurology.

[50]  B. Lipska,et al.  Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. , 1993, Brain research. Developmental brain research.

[51]  J. Vanderhaeghen,et al.  Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum , 1992, Neuroscience Letters.

[52]  P. M. Groves,et al.  A GABA immunocytochemical study of rat motor thalamus: Light and electron microscopic observations , 1991, Neuroscience.

[53]  A. Duchemin,et al.  Preproenkephalin mRNA and Methionine‐Enkephalin Increase in Mouse Striatum After 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Treatment , 1991, Journal of neurochemistry.

[54]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[55]  R. Faull,et al.  The use of c-fos as a metabolic marker in neuronal pathway tracing , 1989, Journal of Neuroscience Methods.

[56]  G Maura,et al.  Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. , 1988, The Journal of pharmacology and experimental therapeutics.

[57]  M. Zigmond,et al.  Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. , 1984, Archives of neurology.

[58]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[59]  P. Jeffrey Conn,et al.  Development of allosteric modulators of GPCRs for treatment of CNS disorders , 2014, Neurobiology of Disease.

[60]  G. Zetler,et al.  Pharmacokinetics and effects of haloperidol in the isolated mouse. , 1985, Pharmacology.